Literature DB >> 19594198

Patients' attitudes towards generic substitution of oral atypical antipsychotics: a questionnaire-based survey in a hypothetical pharmacy setting.

Beatriz Roman1.   

Abstract

BACKGROUND: Generic atypical antipsychotics in tablet form differ in name, appearance and packaging from the innovator brand antipsychotics. These differences might cause anxiety, confusion and misperceptions in some ambulant patients with psychoses/schizophrenia, especially if the brand atypical antipsychotic is substituted in the pharmacy without the acknowledgement of the patient and treating psychiatrist. Furthermore, generic substitution of branded oral atypical antipsychotics in the pharmacy might cause nonadherence and potentially lead to suboptimal treatment outcomes if patients perceive the medicines to be clinically different.
OBJECTIVE: To determine the attitudes of patients with psychoses/schizophrenia towards generic substitution of oral atypical antipsychotics in a pharmacy setting.
METHODS: A total of 106 ambulant patients with psychoses/schizophrenia currently taking an oral atypical antipsychotic (risperidone [Risperdal], olanzapine [Zyprexa], quetiapine [Seroquel] or aripiprazole [Abilify]) were confronted with generic substitution in a hypothetical pharmacy setting.Two conditions were used: one granting patients a short explanation about the substitution, and one without explanation. Patients' attitudes towards the generic substitution were assessed using a combined quantitative and qualitative design.
RESULTS: Of the respondents, 73% stated that they would be unlikely to take a generic antipsychotic if their pharmacist were to substitute it. Providing patients with a short explanation had a significantly positive effect on their intention to take a generic version; however, overall, the patients' intention to take the generic antipsychotic lay well below a neutral midpoint.
CONCLUSION: Patients with psychoses/schizophrenia using atypical antipsychotics in tablet form perceive generic versions of their antipsychotics as being significantly different. This perceived difference lowers their intention of continuing to take the medication, thus possibly jeopardizing treatment outcome. Caution with the generic substitution of atypical antipsychotics in the pharmacy is therefore recommended. Generic substitution should take place only with the knowledge and agreement of the psychiatrist and the patient.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19594198     DOI: 10.2165/00023210-200923080-00006

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  16 in total

1.  Exploring generic drug use behavior: the role of prescribers and pharmacists in the opportunity for generic drug use and generic substitution.

Authors:  David A Mott; Richard R Cline
Journal:  Med Care       Date:  2002-08       Impact factor: 2.983

2.  The bioequivalence and therapeutic efficacy.

Authors:  M Gervasoni; R Pirola; S R Bareggi; C Tonello; E Nisoli; Lita Vialba
Journal:  Clin Ther       Date:  2004-05       Impact factor: 3.393

Review 3.  Therapeutic inequivalence.

Authors:  P H Rheinstein
Journal:  Drug Saf       Date:  1990       Impact factor: 5.606

4.  [The clinical and economic impact of generic drugs in the treatment of epilepsy].

Authors:  A Argumosa; J L Herranz
Journal:  Rev Neurol       Date:  2005 Jul 1-15       Impact factor: 0.870

5.  Clinical effects of a randomized switch of patients from clozaril to generic clozapine.

Authors:  J C Kluznik; N H Walbek; M G Farnsworth; K Melstrom
Journal:  J Clin Psychiatry       Date:  2001       Impact factor: 4.384

6.  Surgically implantable long-term antipsychotic delivery systems for the treatment of schizophrenia.

Authors:  Steven J Siegel; Karen I Winey; Raquel E Gur; Robert H Lenox; Warren B Bilker; Debbie Ikeda; Neel Gandhi; Wen-Xiao Zhang
Journal:  Neuropsychopharmacology       Date:  2002-06       Impact factor: 7.853

7.  Negative symptoms of schizophrenia and compliance with medication.

Authors:  T M Tattan; F H Creed
Journal:  Schizophr Bull       Date:  2001       Impact factor: 9.306

8.  Systematic review of patient and nurse attitudes to depot antipsychotic medication.

Authors:  J Walburn; R Gray; K Gournay; S Quraishi; A S David
Journal:  Br J Psychiatry       Date:  2001-10       Impact factor: 9.319

9.  Bioinequivalence of a generic brand of diazepam.

Authors:  A Locniskar; D J Greenblatt; J S Harmatz; R I Shader
Journal:  Biopharm Drug Dispos       Date:  1989 Nov-Dec       Impact factor: 1.627

10.  Bioequivalence and other unresolved issues in generic drug substitution.

Authors:  Peter Meredith
Journal:  Clin Ther       Date:  2003-11       Impact factor: 3.393

View more
  15 in total

Review 1.  Switching from brand-name to generic psychotropic medications: a literature review.

Authors:  Julie Eve Desmarais; Linda Beauclair; Howard C Margolese
Journal:  CNS Neurosci Ther       Date:  2010-11-30       Impact factor: 5.243

2.  Patient perceptions of generic medicines: a mixed-methods study.

Authors:  Suzanne Dunne; Bill Shannon; Colum Dunne; Walter Cullen
Journal:  Patient       Date:  2014       Impact factor: 3.883

Review 3.  Rational use of generic psychotropic drugs.

Authors:  Maren Carbon; Christoph U Correll
Journal:  CNS Drugs       Date:  2013-05       Impact factor: 5.749

4.  The introduction of generic risperidone in Medicare Part D.

Authors:  Vicki Fung; Mary Price; Alisa B Busch; Mary Beth Landrum; Bruce Fireman; Andrew A Nierenberg; Joseph P Newhouse; John Hsu
Journal:  Am J Manag Care       Date:  2016-01       Impact factor: 2.229

Review 5.  What Do Users of Generic Medicines Think of Them? A Systematic Review of Consumers' and Patients' Perceptions of, and Experiences with, Generic Medicines.

Authors:  Suzanne S Dunne
Journal:  Patient       Date:  2016-12       Impact factor: 3.883

6.  Variations in Patients' Perceptions and Use of Generic Drugs: Results of a National Survey.

Authors:  Aaron S Kesselheim; Joshua J Gagne; Jessica M Franklin; Wesley Eddings; Lisa A Fulchino; Jerry Avorn; Eric G Campbell
Journal:  J Gen Intern Med       Date:  2016-02-16       Impact factor: 5.128

7.  Utilization of Generic Cardiovascular Drugs in Medicare's Part D Program.

Authors:  Iris Ma; Rebecca L Tisdale; Daniel Vail; Paul A Heidenreich; Alexander T Sandhu
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2021-12-09

8.  [Risk factors for treatment adherence in patients with schizophrenia: case-control study].

Authors:  Chadya Aarab; Fatima Elghazouani; Rachid Aalouane; Ismail Rammouz
Journal:  Pan Afr Med J       Date:  2015-03-20

9.  Pharmacy switch of antipsychotic medications: patient's perspective.

Authors:  Slawomir Murawiec; Aleksandra Rajewska-Rager; Jerzy Samochowiec; Sylwia Kalinowska; Jacek Kurpisz; Joanna Krzyzanowska; Halina Sienkiewicz-Jarosz; Iwona Kurkowska-Jastrzebska; Agnieszka Samochowiec; Przemyslaw Bienkowski
Journal:  Ann Gen Psychiatry       Date:  2015-09-25       Impact factor: 3.455

Review 10.  What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugs.

Authors:  Suzanne S Dunne; Colum P Dunne
Journal:  BMC Med       Date:  2015-07-29       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.